Dechra Pharmaceuticals PLC
("Dechra" or the "Company")
Publication of shareholder circular in relation to the proposed disposal of the Services Segment
London, 11 July 2013
For immediate release
The Board of Dechra announced yesterday the proposed sale of the Services Segment (the "Disposal"). In view of its size, the Disposal is conditional, inter alia, upon the approval of Dechra Shareholders, and the Company confirms that a circular containing further details of the Disposal and a Notice convening a General Meeting of the Company to be held at the Company's offices at 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich CW9 7UA at 12.00 noon on 29 July 2013, has today been published and posted to Dechra Shareholders.
In compliance with LR 9.6.1R and LR 9.6.3R, the Company confirms that the Circular and the Form of Proxy have also been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/nsm and on the Company's website at: http://www.dechra.com/.
Enquiries: |
|
Ian Page, Chief Executive |
Fiona Tooley, Director |
Anne-Francoise Nesmes, Chief Financial Officer |
TooleyStreet Communications |
Dechra Pharmaceuticals PLC |
Telephone: +44 (0) 121 309 0099 |
Telephone: + 44 (0) 1606 814730 |
Mobile: +44 (0) 778 570 3523 (FT) |
www.dechra.com |
Ticker: Full Listing (Pharmaceuticals): DPH |
About Dechra
Dechra is an international veterinary pharmaceutical business. Its expertise is in the development, manufacturing, distribution, sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.